Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment

BACKGROUND AND OBJECTIVE: Elexacaftor/tezacaftor/ivacaftor is highly effective in treating people with cystic fibrosis (pwCF) who have ≥ 1 responsive mutation. Liver disease occurs in approximately 10%–20% of pwCF. The objective of this study was to assess the safety and pharmacokinetics of elexacaf...

Descripción completa

Detalles Bibliográficos
Autores principales: Viswanathan, Lakshmi, Bachman, Eric, Tian, Simon, Ahluwalia, Neil, Zhang, Yaohua, Bernstein, Harold S., Panorchan, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633523/
https://www.ncbi.nlm.nih.gov/pubmed/36036885
http://dx.doi.org/10.1007/s13318-022-00791-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633523/
https://www.ncbi.nlm.nih.gov/pubmed/36036885
http://dx.doi.org/10.1007/s13318-022-00791-8

Ejemplares similares